SELECT-LIFE
Research type
Research Study
Full title
SELECT-LIFE (SELECT follow-up study to evaluate Longterm Impact oF anti-obEsity medication)
IRAS ID
300436
Contact name
John Wilding
Contact email
Sponsor organisation
Novo Nordisk Ltd
ISRCTN Number
ISRCTN00000000
Clinicaltrials.gov Identifier
Duration of Study in the UK
10 years, 8 months, 16 days
Research summary
Obesity is currently considered one of the most significant public health challenges worldwide. Obesity is associated with a variety of health-related complications causing increased death such as an increased risk of type 2 diabetes, high blood pressure, abnormal lipid profile (cholesterol tests), diseases that involve the heart or blood vessels (also known as cardiovascular diseases) or other conditions.
This SELECT-LIFE (follow-up study) sponsored by Novo Nordisk is an observational, survey-based follow-up study of the participants who were enrolled in SELECT. SELECT is a cardiovascular outcomes trial which started in 2018 aiming to demonstrate that semaglutide 2.4 mg administered by injection under the skin, once weekly lowers the incidence of major adverse cardiovascular events in patients with established cardiovascular disease and overweight or obesity. This was the first clinical trial designed to explore superiority of GLP-1 RA against placebo, in addition to standard of care on reduction of cardiovascular events in a non-diabetic overweight or obese population.
During the conduct of SELECT, participants will be invited to transition to SELECT-LIFE (follow-up study) when SELECT ends. SELECT-LIFE will look at how many participants get diseases such as heart attack, stroke or other diseases in relation to overweight, and the deaths during the next 10 years. The anticipated number of participants to be included is 12500 (out of the 17500 of the SELECT on-going study).
The study is observational with no study-specific treatment during the study. In this study self-reported data will be collected from the participants by completing a questionnaire every 6 months for up to 10 years.Contact details for participants, participants own doctor (GP) and relative will be collected. They may be contacted for information related to the SELECT-LIFE study and for any follow up if needed.
REC name
HSC REC A
REC reference
21/NI/0172
Date of REC Opinion
31 Jan 2022
REC opinion
Further Information Favourable Opinion